alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › disease-modifying-therapy

disease-modifying-therapy

2 studies tagged disease-modifying-therapy, dated 2021-02-04 to 2024-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy 2024-01-01
  2. Is Korea Prepared for an Alzheimer's Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests 2021-02-04

Studies

2 studies carry this tag.

Date range

2021 to 2024

Top journals

  • Annals of geriatric medicine and research 1
  • The journal of prevention of Alzheimer's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy

    ✓ Peer-reviewed alzhub usefulness score 69 out of 100. The journal of prevention of Alzheimer's disease 2024-01-01 Biomarkers

    A total of 428 participants were included; 167 had normal cognition, 245 had MCI, and 16 had mild AD.

  2. Is Korea Prepared for an Alzheimer's Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of geriatric medicine and research 2021-02-04 Biomarkers

    South Korea's healthcare infrastructure requires more preparation for the introduction of a disease-modifying therapy, with the primary capacity limitation being the low number of dementia specialists.

All topic tags with their study counts